2024-518151-29-00已完成4 期
MOVIE_A phase I/II basket trial evaluating a combination of Metronomic Oral Vinorelbine plus anti-PD-L1/anti-CTLA4 ImmunothErapy in patients with advanced solid tumours.
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Unicancer
- 入组人数
- 126
- 试验地点
- 1
- 主要终点
- Phase I: Determine MTD and the phase II recommended dose (RP2D) of metronomic oral vinorelbine associated with fixed dose of durvalumab + tremelimumab combination in patient with advanced solid tumour. All patients who receive any study treatment are monitored for toxicity and included in the safety analysis. To be evaluable for DLT, a patient must either be observed for full phase I duration period, i.e. 4-week DLT evaluation period from the treatment initiation,or have experienced DLT
研究概览
简要总结
Phase I: To determine the maximum tolerated dose (MTD) and the recommended dose for phase II (RP2D) of metronomic oral vinorelbine associated with durvalumab + tremelimumab combination immunotherapy for the treatment of advanced solid tumours: head and neck, prostate, cervix, and breast cancers, as well as miscellaneous malignancies with high mutational load and/or MSI-High. Phase II: To assess the antitumour activity of metronomic oral vinorelbine associated with durvalumab + tremelimumab combination immunotherapy for the treatment of advanced solid tumours: head and neck, prostate, cervix, and breast cancers, as well as miscellaneous malignancies with high mutational load and/or MSI-High, using the clinical benefit rate (CBR) according to RECIST v1.1.
入排标准
- 年龄范围
- 0 years 至 65+ years（0-17 Years, 65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Patient must have signed a written informed consent form prior to any study specific procedures
- •Normal cardiac function: LVEF ≥50% (any assessment method).
- •Measured Creatinine clearance (Cockcroft and Gault) ≥40 mL/min OR creatinine ≤1.5 times ULN
- •Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients (urine within 72 h, or serum pregnancy test within 14 days prior to enrolment).
- •Patient willing and able to comply with the protocol for the duration of the study including: treatment and scheduled visits during the treatment phase, and visits during follow up.
- •Patient is willing to comply with a baseline tumour biopsy (unless an archived biopsy of a secondary or a primary site of the current disease-collected within 3 months prior enrolment is available for research ; bone metastasis are accepted only when predominant extra-bone tissue is available), and with a series of blood samples throughout the study.
- •Patient must be affiliated to a social health insurance
- •Histologically confirmed locally advanced or metastatic solid tumours, resistant to conventional therapies, and candidate to experimental therapy by local clinical board, from the following primary tumours: ✓ Head and neck squamous cell carcinomas, ✓ Breast cancer, treated with a maximum of 2 lines of chemotherapy in metastatic setting ✓ Prostate cancer, Tumeur Groupe Tumeur d’UNICANCER: MEDECINE PERSONNALISEE N° de Protocole : UC-0101/1709 N° EudraCT : 2017-001857-14 Protocole MOVİE n°: UC-0101/1709 - Version n°8.0 – 03 June 2024 Page 6 / 146 DOC43_Protocole ME_FR_v3.2 - 06-03-2017 ✓ Cervical cancer, ✓ Miscellaneous primary tumours (except melanoma, non-small cell lung cancer [NSCLC], and renal cell cancer) with o a high mutational load, as defined by a molecular clinical board after next-generation sequencing (comprehensive cancer gene panel or whole genome/exome sequencing) analysis. OR o Microsatellite instability (MSI) or mismatch repair (MMR) deficient as determined locally by immunohistochemistry AND polymerase chain-reaction.
- •Patients aged ≥18 years at registration.
- •Life expectancy ≥3 months.
- •Measurable disease according to RECIST v1.
- •ECOG performance status ≤
- •Body weight >30 kg.
- •Normal haematological function (ANC ≥1.5 x 109/L; platelets count ≥100 x 109/L; haemoglobin ≥9.0 g/dL).
- •Normal hepatic function: total bilirubin ≤1.5 upper limit of normal (ULN) (unless documented Gilbert’s syndrome); ASAT and ALAT ≤2.5 ULN (≤5 ULN in the presence of liver metastases).
排除标准
- •Other concurrent malignancies, except adequately treated cone-biopsied in situ carcinoma of the cervix, or basal cell or squamous cell carcinoma of the skin. Patients who have had potentially curative therapy for a prior malignancy are eligible provided there has been no evidence of disease for ≥5 years and the risk of recurrence is considered low.
- •Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab or tremelimumab. The following are exceptions to this criterion: • Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection) • Systemic corticosteroids at physiologic doses ≤10 mg/day of prednisone or its equivalent (see Appendix 7) • Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)
- •Uncontrolled intercurrent illness, including but not limited to, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, clinically significant cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhoea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring adverse events, or compromise the ability of the patient to give written informed consent
- •Patients who have received a live vaccine within 30 days of the planned start of the study treatment(s).
- •Prior anticancer therapy, within the last 3 weeks. It includes radiotherapy (concurrent palliative radiotherapy is allowed), endocrine therapy, immunotherapy, chemotherapy (2 weeks for weekly schedule, 6 weeks for nitrosoureas and mitomycin C), or other investigational agents
- •Major surgery within 28 days prior to the first dose of study treatment. Note: Local surgery of isolated lesions for palliative intent is acceptable
- •Malabsorption syndrome or disease significantly affecting gastro-intestinal function or major resection of the stomach or proximal small bowel that could affect absorption of oral vinorelbine
- •Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria • Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis after consultation with the Study Coordinator. • Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab or tremelimumab may be included only after consultation with the Study Coordinator.
- •Patients enrolled in another clinical study with an investigational product within 21 days of inclusion
- •Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study
- •Female patients who are pregnant or breastfeeding. Male or female patients of reproductive potential who are not willing to employ highly effective methods of contraception from screening to 180 days after receipt of the final dose of durvalumab and tremelimumab in combination or 90 days after the last dose of durvalumab monotherapy or vinorelbine.
- •Active brain metastases, spinal cord compression, or leptomeningeal disease (except local meningeal disease due to local recurrence). Patients whose brain metastases have been treated may participate if the brain metastases are stable by imagery (defined as 2 brain images, both obtained after treatment of the brain metastases and at least four weeks apart, and showing no evidence of intracranial progression). In addition, any neurologic symptoms caused by the brain metastases or their treatment must be resolved or stable, without steroidal treatment or with a dose of steroid ≤10 mg/day of prednisone or its equivalent and an anticonvulsants, for at least 14 days prior to the start of treatment.
- •Persons deprived of their liberty or under protective custody or guardianship
- •Patients with any psychological, family, sociological or geographical problem potentially hampering compliance with the study protocol and follow-up schedule.
- •Previous treatment with an anti-PD1/PD-L1 including durvalumab or an anti-CTLA-4 therapy including tremelimumab or vinorelbine (in advanced setting).
- •Patients with known allergy or severe hypersensitivity to any of the study treatments or any of the study treatment excipients.
- •History of active primary immunodeficiency
- •Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.]). The following are exceptions to this criterion: • Patients with vitiligo or alopecia. • Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement therapy. • Any chronic skin condition that does not require systemic therapy.Patients without active disease in the last 5 years may be included but only after consultation with the study physician. • Patients with celiac disease controlled by diet alone.
- •History of allogeneic organ transplantation.
- •History or evidence of active, non-infectious pneumonitis
- •Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
结局指标
主要结局
Phase I: Determine MTD and the phase II recommended dose (RP2D) of metronomic oral vinorelbine associated with fixed dose of durvalumab + tremelimumab combination in patient with advanced solid tumour. All patients who receive any study treatment are monitored for toxicity and included in the safety analysis. To be evaluable for DLT, a patient must either be observed for full phase I duration period, i.e. 4-week DLT evaluation period from the treatment initiation,or have experienced DLT
Phase I: Determine MTD and the phase II recommended dose (RP2D) of metronomic oral vinorelbine associated with fixed dose of durvalumab + tremelimumab combination in patient with advanced solid tumour. All patients who receive any study treatment are monitored for toxicity and included in the safety analysis. To be evaluable for DLT, a patient must either be observed for full phase I duration period, i.e. 4-week DLT evaluation period from the treatment initiation,or have experienced DLT
Phase2:CBR defined as the rate of complete response (CR), partial response (PR), or SD lasting at least 24 weeks according to RECIST v1.1 and will be evaluated based on the best response status obtained until 24 weeks after starting treatment. Analysis of the primary endpoint will be carried out sequentially with interim analyses planned after 24 weeks of follow up of the first 10 patients of each cohort and then every 5 patients. At each analysis the Bayesian model will be updated
Phase2:CBR defined as the rate of complete response (CR), partial response (PR), or SD lasting at least 24 weeks according to RECIST v1.1 and will be evaluated based on the best response status obtained until 24 weeks after starting treatment. Analysis of the primary endpoint will be carried out sequentially with interim analyses planned after 24 weeks of follow up of the first 10 patients of each cohort and then every 5 patients. At each analysis the Bayesian model will be updated
次要结局
- ORR, iORR, the iCBR24 will be presented with the associated 95% confidence intervals (CIs).
- PFS, iPFS, OS, DoR, and iDoR will be estimated using the Kaplan-Meier method and will be described in terms of medians with the associated 95% CIs.
- The safety will be evaluated using the incidence of treatment emergent adverse events (TEAE), serious adverse Events (SAE), and deaths. Tolerance will be assessed by NCI-CTCAE v5.0 scale. Descriptive statistics will be provided for characterising and assessing patient tolerance to treatment.
研究者
Nourredine AIT RAHMOUNE
Scientific
Unicancer
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Phase 1/2 Study of Belzutifan Plus Palbociclib Versus Belzutifan in Advanced Renal Cell Carcinoma (RCC)2023-504963-17-00Merck Sharp & Dohme LLC76
招募中
3 期
A Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus BSC versus Placebo plus BSC in Participants with IPSS-R Low- or Intermediate-risk MDS2022-500479-29-00Celgene Corp.166
招募中
2 期
Phase 2 Trial to determine the safety and efficacy of simultaneous treatment with ruxolitinib and extracorporeal photopheresis for patients with steroid-refractory chronic Graft-versus-Host-Disease (SR-cGvHD) - RUX-ECP2023-507754-33-00Medical Center - University Of Freiburg40
已完成
1 期
A phase 1/2a study to evaluate the dose, safety, tolerability, and efficacy of an intraperitoneal α-emitting radionuclide therapy (Radspherin®) in subjects with peritoneal carcinomatosis from colorectal carcinoma following hyperthermic intraperitoneal chemotherapy2024-511853-23-00Oncoinvent ASA54
已完成
2 期
A Phase 1/2 Study of AMG 193 in Combination with IDE397 in Subjects with Advanced MTAP-null Solid Tumors2023-504364-42-00Amgen Inc.12